Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM). It binds the beta5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity. In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell...

White solid. Soluble in DMSO, ethanol or methanol. Slightly soluble in water. Highly potent, selective and reversible cell permeable inhibitor of the proteasome. Inhibits the chymotrypsin-like and caspase-like peptidase activity of the proteasome, Calpain and cathepsin inhibitor, Autophagy activator, Anticancer...

Soluble in DMSO at 200 mg/mL, soluble in ethanol at 200 mg/mL, very poorly soluble in water, maximum solubility in plain water is estimated to be about 5-10 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility

Proteasome inhibitor.

Bortezomib is the active ingredient in the drug sold under the trade name Velcade(R). This drug has been approved in at least one country to treat multiple myeloma. It is a potent (Ki, 0.6nM), specific and reversible proteasome inhibitor. There is not any significant inhibitory activity against other enzymes or...